COMPOUND PROFILE / PEPTIDES & ANALOGUES
Mazdutide.
Research draftMazdutide is a dual GLP-1 and glucagon receptor agonist.
Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.
Targeted source and identity review, not a systematic review or complete regulatory audit.
Overview
Mazdutide is a dual GLP-1 and glucagon receptor agonist.
Mechanism
It combines appetite-related and glucagon-mediated metabolic actions.
Human research
Randomised studies support diabetes and weight-management development; results depend on population and endpoints.
Preclinical & other research
Animal and receptor work examined metabolic activity.
Safety & unknowns
Gastrointestinal effects and heart-rate or metabolic findings require trial-specific assessment.
Regulatory status
The developer reports Chinese authorisation for defined indications; this is not evidence of US or UK approval.
Reported use & evidence
The supplied Mazdutide profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.
Sources & references
Follow the cited records and registered research. Profiles remain research drafts.